Loading…
Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice
To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice. MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October...
Saved in:
Published in: | Urology (Ridgewood, N.J.) N.J.), 2020-11, Vol.145, p.204-210 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93 |
---|---|
cites | cdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93 |
container_end_page | 210 |
container_issue | |
container_start_page | 204 |
container_title | Urology (Ridgewood, N.J.) |
container_volume | 145 |
creator | Lebastchi, Amir H. Russell, Christopher M. Niknafs, Yashar S. Eyrich, Nicholas W. Chopra, Zoey Botbyl, Rachel Kabeer, Rana Osawa, Takahiro Siddiqui, Javed Siddiqui, Rabia Davenport, Matthew S. Mehra, Rohit Tomlins, Scott A. Kunju, Lakshimi P. Chinnaiyan, Arul M. Wei, John T. Tosoian, Jeffrey J. Morgan, Todd M. |
description | To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice.
MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model.
Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P < .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P < .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; |
doi_str_mv | 10.1016/j.urology.2020.07.042 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2432863494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090429520309560</els_id><sourcerecordid>2432863494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvhEUA-lkPC2PHaMRdUFgqVWlHR9mw5zqR4lcTBTpD2GXhpvOyWK6eRRt8_M__8hLxmUDJg8t22XGLow8Ou5MChBFWC4E_Iiq25KrTW66dkBaChEFyvT8iLlLYAIKVUz8lJxZVSlYIV-X05TNbNNHR0_oH0encTQ5rtjLcuRKRn1ze3b-kdpkyMf4lN70fvbE8_ofPJ77uB3o8txodAH8X0ow9T2r2n3zEt_ZzoRQwDtXQTxhmHKUQbd_Tc2RYH77IqX-AdviTPOtsnfHWsp-T-4vPd5mtx9e3L5eb8qnCC8blgTFUtCgWSV9Bo1TSWNdgxkLWsG-644AyalkOrHGuqrmOiRS3r2taZs7o6JWeHuVMMP5fszQw-Oex7O2JYkuGi4rWshBYZXR9Ql52liJ2Zoh_y9YaB2edgtuaYg9nnYECZnEPWvTmuWJoB23-qx8dn4MMBwGz0l8dokvM4Omx9RDebNvj_rPgD9kudKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2432863494</pqid></control><display><type>article</type><title>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</title><source>Elsevier</source><creator>Lebastchi, Amir H. ; Russell, Christopher M. ; Niknafs, Yashar S. ; Eyrich, Nicholas W. ; Chopra, Zoey ; Botbyl, Rachel ; Kabeer, Rana ; Osawa, Takahiro ; Siddiqui, Javed ; Siddiqui, Rabia ; Davenport, Matthew S. ; Mehra, Rohit ; Tomlins, Scott A. ; Kunju, Lakshimi P. ; Chinnaiyan, Arul M. ; Wei, John T. ; Tosoian, Jeffrey J. ; Morgan, Todd M.</creator><creatorcontrib>Lebastchi, Amir H. ; Russell, Christopher M. ; Niknafs, Yashar S. ; Eyrich, Nicholas W. ; Chopra, Zoey ; Botbyl, Rachel ; Kabeer, Rana ; Osawa, Takahiro ; Siddiqui, Javed ; Siddiqui, Rabia ; Davenport, Matthew S. ; Mehra, Rohit ; Tomlins, Scott A. ; Kunju, Lakshimi P. ; Chinnaiyan, Arul M. ; Wei, John T. ; Tosoian, Jeffrey J. ; Morgan, Todd M.</creatorcontrib><description>To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice.
MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model.
Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P < .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P < .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; <.001) and binary (OR 7.76, 95%; CI 4.14-14.5; P < .001) variable.
Many patients (46%) undergoing clinical MPS testing as an alternative to immediate prostate biopsy were able to avoid biopsy. Increasing MPS was strongly associated with biopsy rates. These findings were robust to use of mpMRI.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/j.urology.2020.07.042</identifier><identifier>PMID: 32777370</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antigens, Neoplasm - urine ; Biopsy ; Clinical Decision-Making ; Cohort Studies ; Humans ; Male ; Middle Aged ; Multiparametric Magnetic Resonance Imaging ; Prostate - diagnostic imaging ; Prostate - pathology ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - urine</subject><ispartof>Urology (Ridgewood, N.J.), 2020-11, Vol.145, p.204-210</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</citedby><cites>FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32777370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lebastchi, Amir H.</creatorcontrib><creatorcontrib>Russell, Christopher M.</creatorcontrib><creatorcontrib>Niknafs, Yashar S.</creatorcontrib><creatorcontrib>Eyrich, Nicholas W.</creatorcontrib><creatorcontrib>Chopra, Zoey</creatorcontrib><creatorcontrib>Botbyl, Rachel</creatorcontrib><creatorcontrib>Kabeer, Rana</creatorcontrib><creatorcontrib>Osawa, Takahiro</creatorcontrib><creatorcontrib>Siddiqui, Javed</creatorcontrib><creatorcontrib>Siddiqui, Rabia</creatorcontrib><creatorcontrib>Davenport, Matthew S.</creatorcontrib><creatorcontrib>Mehra, Rohit</creatorcontrib><creatorcontrib>Tomlins, Scott A.</creatorcontrib><creatorcontrib>Kunju, Lakshimi P.</creatorcontrib><creatorcontrib>Chinnaiyan, Arul M.</creatorcontrib><creatorcontrib>Wei, John T.</creatorcontrib><creatorcontrib>Tosoian, Jeffrey J.</creatorcontrib><creatorcontrib>Morgan, Todd M.</creatorcontrib><title>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice.
MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model.
Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P < .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P < .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; <.001) and binary (OR 7.76, 95%; CI 4.14-14.5; P < .001) variable.
Many patients (46%) undergoing clinical MPS testing as an alternative to immediate prostate biopsy were able to avoid biopsy. Increasing MPS was strongly associated with biopsy rates. These findings were robust to use of mpMRI.</description><subject>Aged</subject><subject>Antigens, Neoplasm - urine</subject><subject>Biopsy</subject><subject>Clinical Decision-Making</subject><subject>Cohort Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiparametric Magnetic Resonance Imaging</subject><subject>Prostate - diagnostic imaging</subject><subject>Prostate - pathology</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - urine</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkcFu1DAQhi0EokvhEUA-lkPC2PHaMRdUFgqVWlHR9mw5zqR4lcTBTpD2GXhpvOyWK6eRRt8_M__8hLxmUDJg8t22XGLow8Ou5MChBFWC4E_Iiq25KrTW66dkBaChEFyvT8iLlLYAIKVUz8lJxZVSlYIV-X05TNbNNHR0_oH0encTQ5rtjLcuRKRn1ze3b-kdpkyMf4lN70fvbE8_ofPJ77uB3o8txodAH8X0ow9T2r2n3zEt_ZzoRQwDtXQTxhmHKUQbd_Tc2RYH77IqX-AdviTPOtsnfHWsp-T-4vPd5mtx9e3L5eb8qnCC8blgTFUtCgWSV9Bo1TSWNdgxkLWsG-644AyalkOrHGuqrmOiRS3r2taZs7o6JWeHuVMMP5fszQw-Oex7O2JYkuGi4rWshBYZXR9Ql52liJ2Zoh_y9YaB2edgtuaYg9nnYECZnEPWvTmuWJoB23-qx8dn4MMBwGz0l8dokvM4Omx9RDebNvj_rPgD9kudKw</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Lebastchi, Amir H.</creator><creator>Russell, Christopher M.</creator><creator>Niknafs, Yashar S.</creator><creator>Eyrich, Nicholas W.</creator><creator>Chopra, Zoey</creator><creator>Botbyl, Rachel</creator><creator>Kabeer, Rana</creator><creator>Osawa, Takahiro</creator><creator>Siddiqui, Javed</creator><creator>Siddiqui, Rabia</creator><creator>Davenport, Matthew S.</creator><creator>Mehra, Rohit</creator><creator>Tomlins, Scott A.</creator><creator>Kunju, Lakshimi P.</creator><creator>Chinnaiyan, Arul M.</creator><creator>Wei, John T.</creator><creator>Tosoian, Jeffrey J.</creator><creator>Morgan, Todd M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202011</creationdate><title>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</title><author>Lebastchi, Amir H. ; Russell, Christopher M. ; Niknafs, Yashar S. ; Eyrich, Nicholas W. ; Chopra, Zoey ; Botbyl, Rachel ; Kabeer, Rana ; Osawa, Takahiro ; Siddiqui, Javed ; Siddiqui, Rabia ; Davenport, Matthew S. ; Mehra, Rohit ; Tomlins, Scott A. ; Kunju, Lakshimi P. ; Chinnaiyan, Arul M. ; Wei, John T. ; Tosoian, Jeffrey J. ; Morgan, Todd M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Antigens, Neoplasm - urine</topic><topic>Biopsy</topic><topic>Clinical Decision-Making</topic><topic>Cohort Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiparametric Magnetic Resonance Imaging</topic><topic>Prostate - diagnostic imaging</topic><topic>Prostate - pathology</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lebastchi, Amir H.</creatorcontrib><creatorcontrib>Russell, Christopher M.</creatorcontrib><creatorcontrib>Niknafs, Yashar S.</creatorcontrib><creatorcontrib>Eyrich, Nicholas W.</creatorcontrib><creatorcontrib>Chopra, Zoey</creatorcontrib><creatorcontrib>Botbyl, Rachel</creatorcontrib><creatorcontrib>Kabeer, Rana</creatorcontrib><creatorcontrib>Osawa, Takahiro</creatorcontrib><creatorcontrib>Siddiqui, Javed</creatorcontrib><creatorcontrib>Siddiqui, Rabia</creatorcontrib><creatorcontrib>Davenport, Matthew S.</creatorcontrib><creatorcontrib>Mehra, Rohit</creatorcontrib><creatorcontrib>Tomlins, Scott A.</creatorcontrib><creatorcontrib>Kunju, Lakshimi P.</creatorcontrib><creatorcontrib>Chinnaiyan, Arul M.</creatorcontrib><creatorcontrib>Wei, John T.</creatorcontrib><creatorcontrib>Tosoian, Jeffrey J.</creatorcontrib><creatorcontrib>Morgan, Todd M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lebastchi, Amir H.</au><au>Russell, Christopher M.</au><au>Niknafs, Yashar S.</au><au>Eyrich, Nicholas W.</au><au>Chopra, Zoey</au><au>Botbyl, Rachel</au><au>Kabeer, Rana</au><au>Osawa, Takahiro</au><au>Siddiqui, Javed</au><au>Siddiqui, Rabia</au><au>Davenport, Matthew S.</au><au>Mehra, Rohit</au><au>Tomlins, Scott A.</au><au>Kunju, Lakshimi P.</au><au>Chinnaiyan, Arul M.</au><au>Wei, John T.</au><au>Tosoian, Jeffrey J.</au><au>Morgan, Todd M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>2020-11</date><risdate>2020</risdate><volume>145</volume><spage>204</spage><epage>210</epage><pages>204-210</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><abstract>To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice.
MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model.
Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P < .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P < .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; <.001) and binary (OR 7.76, 95%; CI 4.14-14.5; P < .001) variable.
Many patients (46%) undergoing clinical MPS testing as an alternative to immediate prostate biopsy were able to avoid biopsy. Increasing MPS was strongly associated with biopsy rates. These findings were robust to use of mpMRI.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32777370</pmid><doi>10.1016/j.urology.2020.07.042</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-4295 |
ispartof | Urology (Ridgewood, N.J.), 2020-11, Vol.145, p.204-210 |
issn | 0090-4295 1527-9995 |
language | eng |
recordid | cdi_proquest_miscellaneous_2432863494 |
source | Elsevier |
subjects | Aged Antigens, Neoplasm - urine Biopsy Clinical Decision-Making Cohort Studies Humans Male Middle Aged Multiparametric Magnetic Resonance Imaging Prostate - diagnostic imaging Prostate - pathology Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - pathology Prostatic Neoplasms - urine |
title | Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A04%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20the%20MyProstateScore%20(MPS)%20Test%20on%20the%20Clinical%20Decision%20to%20Undergo%20Prostate%20Biopsy:%20Results%20From%20a%20Contemporary%20Academic%20Practice&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Lebastchi,%20Amir%20H.&rft.date=2020-11&rft.volume=145&rft.spage=204&rft.epage=210&rft.pages=204-210&rft.issn=0090-4295&rft.eissn=1527-9995&rft_id=info:doi/10.1016/j.urology.2020.07.042&rft_dat=%3Cproquest_cross%3E2432863494%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2432863494&rft_id=info:pmid/32777370&rfr_iscdi=true |